Total Eye Care, PA Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT02188160
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Eugene B. McLaurin, M.D., F.A.C.S. | Total Eye Care | Total Eye Care, PA

Active Ingredients

Drugs in Phase 2 Trials (2)

loteprednol (lotemax) (1 trial)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Keratoconjunctivitis (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Signs and Symptoms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2